The research of Peter A. Noseworthy, M.D., focuses on the pathophysiology and management of atrial and ventricular arrhythmias. In particular, Dr. Noseworthy is working to identify genetic determinants of ventricular arrhythmia, develop noninvasive means for arrhythmia risk stratification, refine catheter-based ablation techniques and study health outcomes in patients undergoing cardiac ablation.
- Genetics of ventricular arrhythmia. Dr. Noseworthy's research focuses on identifying genetic contributors to risk of sudden cardiac death, QT prolongation and drug-induced arrhythmias. He is currently creating a database of genetic material collected from individuals undergoing electrophysiologic evaluation at Mayo clinic. This biobank will provide a risk database for the study of genetic influences on a variety of arrhythmias and clinical outcomes.
- Risk stratification for ventricular arrhythmia. In collaboration with others in the Heart Rhythm Center, Dr. Noseworthy is refining electrocardiographic techniques to identify patients at risk of life-threatening arrhythmias. Current work focuses on electrocardiographic signatures for risk in hypertrophic cardiomyopathy and drug-induced proarrhythmia.
- Outcomes after catheter ablation. Dr. Noseworthy is working with the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery to study outcomes after catheter ablation. Current work focuses on predictors of cardioembolic stroke and arrhythmia recurrence and health care delivery outcomes, such as hospital readmission and cost.
Significance to patient care
Dr. Noseworthy's work aims to improve outcomes in patients with cardiac arrhythmias by identifying patients at risk of adverse events and tailoring therapies to maximize benefit. His work also contributes to the increased safety and efficacy of catheter ablation techniques.